Drug
Bnt323 DB 1303
Bnt323 DB 1303: highest development phase Phase 3, developed by BioNTech. 1 trial record tracked on RxWires.
- Highest phase
- Phase 3
- Developer
- BioNTech
Trials
| Drug | Phase | Indication |
|---|---|---|
| BNT323/DB-1303 NCT06340568 | Phase 3 | Endometrial Cancer |
Latest
No recent events.
Follow Bnt323 DB 1303 on RxWires to get trial status changes, FDA actions, filings and patent dates as they happen.
Sourced from ClinicalTrials.gov, openFDA, SEC EDGAR and the FDA Orange Book. Not investment or medical advice.